MAPK/ERK signaling in osteosarcomas, Ewing sarcomas and chondrosarcomas: Therapeutic implications and future directions

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Chandhanayingyong, Chandhanarat ^a,b   Kim, Yuhree ^a   Staples, J Robert ^a   Hahn, Cody ^a   Lee, Francis Youngin ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CP 751 871; DOXORUBICIN; GANITUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NVP AEW 541; R 1507; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHONDROSARCOMA; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; EWING SARCOMA; GAIN OF FUNCTION MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ORTHOPEDIC SURGERY; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84861019279     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/404810     Document Type: Review

References (70)

1. Mirabello L., Troisi R. J., Savage S. A., Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program Cancer 2009 115 7 1531 1543
2. Link M. P., Goorin A. M., Miser A. W., The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity New England Journal of Medicine 1986 314 25 1600 1606 (Pubitemid 16118216)
3. Bacci G., Longhi A., Versari M., Mercuri M., Briccoli A., Picci P., Prognostic factors for osteosarcoma of the extremity trerated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution Cancer 2006 106 5 1154 1161
4. Mankin H. J., Hornicek F. J., Rosenberg A. E., Harmon D. C., Gebhardt M. C., Survival data for 648 patients with osteosarcoma treated at one institution Clinical Orthopaedics and Related Research 2004 429 286 291 (Pubitemid 39579224)
5. Lee F. Y., Mankin H. J., Fondren G., Gebhardt M. C., Springfield D. S., Rosenberg A. E., Jennings L. C., Chondrosarcoma of bone: an assessment of outcome Journal of Bone and Joint Surgery A 1999 81 3 326 338 (Pubitemid 29153210)
6. Lee F. Y., Onishi A. C., Hincker A. M., Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets Sarcoma 2011 2011 8
7. Dhanasekaran D. N., Johnson G. L., MAPKs: function, regulation, role in cancer and therapeutic targeting Oncogene 2007 26 22 3097 3099 (Pubitemid 46763009)
8. Dhillon A. S., Hagan S., Rath O., Kolch W., MAP kinase signalling pathways in cancer Oncogene 2007 26 22 3279 3290 (Pubitemid 46763021)
9. Bayley J.-P., Devilee P., The warburg effect in 2012 Current Opinion in Oncology 2012 24 1 62 67
10. Eves E. M., Rosner M. R., MAP kinase regulation of the mitotic spindle checkpoint Methods in Molecular Biology 2010 661 497 505
11. Lee H. G., Minematsu H., Kim K. O., Celil Aydemir A. B., Shin M. J., Nizami S. A., Chung K. J., Hsu A. C., Jacobs C. R., Lee F. Y., Actin and ERK1/2-CEBP signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells Biomaterials 2011 32 35 9197 9206
12. Mielgo A., Seguin L., Huang M., Camargo M. F., Anand S., Franovic A., Weis S. M., Advani S. J., Murphy E. A., Cheresh D. A., A MEK-independent role for CRAF in mitosis and tumor progression Nature Medicine 2011 17 1641 1645
13. Zeng Q., Li S., Chepeha D. B., Giordano T. J., Li J., Zhang H., Polverini P. J., Nor J., Kitajewski J., Wang C. Y., Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling Cancer Cell 2005 8 1 13 23 (Pubitemid 40991811)
14. Seo S. W., Lee D., Minematsu H., Kim A. D., Shin M., Cho S. K., Kim D. W., Yang J., Lee F. Y., Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis Bone 2010 46 3 695 702
15. Hanahan D., Weinberg R. A., The hallmarks of cancer Cell 2000 100 1 57 70 (Pubitemid 30046295)
16. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation Cell 2011 144 5 646 674
17. McGlynn L. M., Kirkegaard T., Edwards J., Tovey S., Cameron D., Twelves C., Bartlett J. M. S., Cooke T. G., Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients Clinical Cancer Research 2009 15 4 1487 1495
18. Atmaca A., Pauligk C., Steinmetz K., Altmannsberger H.-M., Jger E., Al-Batran S.-E., Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer Oncology 2011 80 1-2 130 134
19. Pelloski C. E., Lin E., Zhang L., Yung W. K. A., Colman H., Liu J. L., Woo S. Y., Heimberger A. B., Suki D., Prados M., Chang S., Barker F. G., Fuller G. N., Aldape K. D., Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma Clinical Cancer Research 2006 12 13 3935 3941 (Pubitemid 44078078)
20. Banerji U., Camidge D. R., Verheul H. M. W., Agarwal R., Sarker D., Kaye S. B., Desar I. M. E., Timmer-Bonte J. N. H., Eckhardt S. G., Lewis K. D., Brown K. H., Cantarini M. V., Morris C., George S. M. A., Smith P. D., Van Herpen C. M. L., The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer Clinical Cancer Research 2010 16 5 1613 1623
21. Hainsworth J. D., Cebotaru C. L., Kanarev V., Ciuleanu T. E., Damyanov D., Stella P., Ganchev H., Pover G., Morris C., Tzekova V., A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens Journal of Thoracic Oncology 2010 5 10 1630 1636
22. O'Neil B. H., Goff L. W., Kauh J. S. W., Strosberg J. R., Bekaii-Saab T. S., Lee R. -M., Kazi A., Moore D. T., Learoyd M., Lush R. M., Sebti S. M., Sullivan D. M., Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma Journal of Clinical Oncology 2011 29 17 2350 2356
23. Unni K. K., Inwards C. Y., Dahlin D. C., Dahlin's Bone Tumors: General Aspects and Data on 10,165 Cases 2009 9th Philadelphia, Pa, USA Lippincott Williams and Wilkins
24. Noh K., Kim K.-O., Patel N. R., Staples J. R., Minematsu H., Nair K., Lee F. Y.-I., Targeting inflammatory kinase as an adjuvant treatment for osteosarcomas Journal of Bone and Joint Surgery A 2011 93 8 723 732
25. Sasaki K., Hitora T., Nakamura O., Kono R., Yamamoto T., The role of MAPK pathway in bone and soft tissue tumors Anticancer Research 2011 31 2 549 553
26. Yu Y., Luk F., Yang J.-L., Walsh W. R., Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model Anticancer Research 2011 31 4 1147 1152
27. Yang R., Piperdi S., Gorlick R., Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase Kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma Clinical Cancer Research 2008 14 20 6396 6404
28. Messerschmitt P. J., Rettew A. N., Brookover R. E., Garcia R. M., Getty P. J., Greenfield E. M., Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro Clinical Orthopaedics and Related Research 2008 466 9 2168 2175
29. Shimo T., Matsumura S., Ibaragi S., Specific inhibitor of MEK-mediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells Journal of Cell Communication and Signaling 2007 1 2 103 111
30. Huang C. Y., Lee C. Y., Chen M. Y., Yang W. H., Chen Y. H., Chang C. H., Hsu H. C., Fong Y. C., Tang C. H., Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF- B-dependent pathways Journal of Cellular Physiology 2009 221 1 204 212
31. Anders Kolb E., Gorlick R., Houghton P. J., Morton C. L., Lock R., Carol H., Patrick Reynolds C., Maris J. M., Keir S. T., Billups C. A., Smith M. A., Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program Pediatric Blood and Cancer 2008 50 6 1190 1197 (Pubitemid 351555543)
32. Kolb E. A., Kamara D., Zhang W., Lin J., Hingorani P., Baker L., Houghton P., Gorlick R., R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts Pediatric Blood and Cancer 2010 55 1 67 75
33. Tolcher A. W., Sarantopoulos J., Patnaik A., Papadopoulos K., Lin C. C., Rodon J., Murphy B., Roth B., McCaffery I., Gorski K. S., Kaiser B., Zhu M., Deng H., Friberg G., Puzanov I., Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 Journal of Clinical Oncology 2009 27 34 5800 5807
34. Montagut C., Settleman J., Targeting the RAF-MEK-ERK pathway in cancer therapy Cancer Letters 2009 283 2 125 134
35. Pignochino Y., Grignani G., Cavalloni G., Motta M., Tapparo M., Bruno S., Bottos A., Gammaitoni L., Migliardi G., Camussi G., Alberghini M., Torchio B., Ferrari S., Bussolino F., Fagioli F., Picci P., Aglietta M., Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways Molecular Cancer 2009 8, article no. 118
36. Keir S. T., Maris J. M., Lock R., Kolb E. A., Gorlick R., Carol H., Morton C. L., Reynolds C. P., Kang M. H., Watkins A., Houghton P. J., Smith M. A., Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program Pediatric Blood and Cancer 2010 55 6 1126 1133
37. Grignani G., Palmerini E., Dileo P., A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study Annals of Oncology 2011
38. Yamamoto T., Ohno T., Wakahara K., Nagano A., Kawai G., Saitou M., Takigami I., Matsuhashi A., Yamada K., Shimizu K., Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma Journal of Cancer Research and Clinical Oncology 2009 135 8 1125 1136
39. Widermann B., Fox E., Adamson C., Baruchel S., Kim A., Ingle A. M., Bender J. G., Stempak D., Balis F. M., Blaney S. M., Phase I study of sorafenib in children with refractory solid tumors: a Children's Oncology Group Phase I Consortium trial Proceedings of the ASCO Annual Meeting 2009
40. Pacey S., Ratain M. J., Flaherty K. T., Kaye S. B., Cupit L., Rowinsky E. K., Xia C., O'Dwyer P. J., Judson I. R., Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Investigational New Drugs 2009 29 3 481 488
41. Maki R. G., D'Adamo D. R., Keohan M. L., Saulle M., Schuetze S. M., Undevia S. D., Livingston M. B., Cooney M. M., Hensley M. L., Mita M. M., Takimoto C. H., Kraft A. S., Elias A. D., Brockstein B., Blachre N. E., Edgar M. A., Schwartz L. H., Qin L. X., Antonescu C. R., Schwartz G. K., Phase II study of sorafenib in patients with metastatic or recurrent sarcomas Journal of Clinical Oncology 2009 27 19 3133 3140
42. Abdeen A., Chou A. J., Healey J. H., Khanna C., Osborne T. S., Hewitt S. M., Kim M., Wang D., Moody K., Gorlick R., Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma Cancer 2009 115 22 5243 5250
43. DuBois S. G., Shusterman S., Ingle A. M., Ahern C. H., Reid J. M., Wu B., Baruchel S., Glade-Bender J., Ivy P., Grier H. E., Adamson P. C., Blaney S. M., Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study Clinical Cancer Research 2011 17 15 5113 5122
44. Barr F. G., Womer R. B., Molecular diagnosis of Ewing family tumors too many fusions...? Journal of Molecular Diagnostics 2007 9 4 437 440 (Pubitemid 47434109)
45. Delattre O., Zucman J., Plougastel B., Desmaze C., Melot T., Peter M., Kovar H., Joubert I., De Jong P., Rouleau G., Aurias A., Thomas G., Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours Nature 1992 359 6391 162 165
46. Cironi L., Riggi N., Provero P., Wolf N., Suv M. L., Suv D., Kindler V., Stamenkovic I., IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells PLoS One 2008 3 7
47. Benini S., Manara M. C., Cerisano V., Perdichizzi S., Strammiello R., Serra M., Picci P., Scotlandi K., Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects International Journal of Cancer 2004 108 3 358 366 (Pubitemid 37549600)
48. Silvany R. E., Eliazer S., Wolff N. C., Ilaria R. L., Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation Oncogene 2000 19 39 4523 4530
49. Kim S. Y., Toretsky J. A., Scher D., Helman L. J., The role of IGF-1R in pediatric malignancies Oncologist 2009 14 1 83 91
50. Toretsky J. A., Kalebic T., Blakesley V., LeRoith D., Helman L. J., The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts Journal of Biological Chemistry 1997 272 49 30822 30827 (Pubitemid 27527522)
51. Zenali M. J., Zhang P. L., Bendel A. E., Brown R. E., Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors Annals of Clinical and Laboratory Science 2009 39 2 160 166
52. Kurmasheva R. T., Dudkin L., Billups C., Debelenko L. V., Morton C. L., Houghton P. J., The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma Cancer Research 2009 69 19 7662 7671
53. Manara M. C., Landuzzi L., Nanni P., Nicoletti G., Zambelli D., Lollini P. L., Nanni C., Hofmann F., Garca-Echeverra C., Picci P., Scotlandi K., Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma Clinical Cancer Research 2007 13 4 1322 1330 (Pubitemid 46424074)
54. Subbiah V., Naing A., Brown R. E., Chen H., Doyle L., LoRusso P., Benjamin R., Anderson P., Kurzrock R., Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures PLoS One 2011 6 4, article e18424
55. Kurzrock R., Patnaik A., Aisner J., Warren T., Leong S., Benjamin R., Eckhardt S. G., Eid J. E., Greig G., Habben K., McCarthy C. D., Gore L., A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors Clinical Cancer Research 2010 16 8 2458 2465
56. Olmos D., Postel-Vinay S., Molife L. R., Okuno S. H., Schuetze S. M., Paccagnella M. L., Batzel G. N., Yin D., Pritchard-Jones K., Judson I., Worden F. P., Gualberto A., Scurr M., de Bono J. S., Haluska P., Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study The Lancet Oncology 2010 11 2 129 135
57. Bond M., Bernstein M. L., Pappo A., Schultz K. R., Krailo M., Blaney S. M., Adamson P. C., A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a children's oncology group study Pediatric Blood and Cancer 2008 50 2 254 258
58. Subbiah V., Anderson P., Targeted therapy of Ewing's sarcoma Sarcoma 2011 2011 10
59. Seong S. C., Matsumura T., Lee F. Y., Whelan M. C., Xiao Qing Li, Trippel S. B., Insulin-like growth factor I regulation of swarm rat chondrosarcoma chondrocytes in culture Experimental Cell Research 1994 211 2 238 244 (Pubitemid 24174953)
60. Lu X., Tang X., Guo W., Ren T., Zhao H., Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway Journal of Surgical Oncology 2010 102 7 821 826
61. Jiang X., Dutton C. M., Qi W. N., Block J. A., Garamszegi N., Scully S. P., siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line Journal of Cellular Physiology 2005 202 3 723 730 (Pubitemid 40175848)
62. Yuan J., Dutton C. M., Scully S. P., RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion Journal of Orthopaedic Research 2005 23 6 1467 1474 (Pubitemid 41554684)
63. Chen Y. J., Wei Y. Y., Chen H. T., Fong Y. C., Hsu C. J., Tsai C. H., Hsu H. C., Liu S. H., Tang C. H., Osteopontin increases migration and MMP-9 up-regulation via v 3 integrin, FAK, ERK, and NF- B-dependent pathway in human chondrosarcoma cells Journal of Cellular Physiology 2009 221 1 98 108
64. Seales E. C., Jurado G. A., Brunson B. A., Wakefield J. K., Frost A. R., Bellis S. L., Hypersialylation of 1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility Cancer Research 2005 65 11 4645 4652 (Pubitemid 40740800)
65. Yao E. S., Zhang H., Chen Y. Y., Lee B., Chew K., Moore D., Park C., Increased 1 integrin is associated with decreased survival in invasive breast cancer Cancer Research 2007 67 2 659 664 (Pubitemid 46192205)
66. Lai T. H., Fong Y. C., Fu W. M., Yang R. S., Tang C. H., Stromal cell-derived factor-1 increase v 3 integrin expression and invasion in human chondrosarcoma cells Journal of Cellular Physiology 2009 218 2 334 342
67. Fong Y. C., Li T. M., Wu C. M., Hsu S. F., Kao S. T., Chen R. J., Lin C. C., Liu S. C., Wu C. L., Tang C. H., BMP-2 increases migration of human chondrosarcoma cells via PI3K/Akt pathway Journal of Cellular Physiology 2008 217 3 846 855
68. Yeh Y. Y., Chiao C. C., Kuo W. Y., Hsiao Y. C., Chen Y. J., Wei Y. Y., Lai T. H., Fong Y. C., Tang C. H., TGF- 1 increases motility and v 3 integrin up-regulation via PI3K, Akt and NF- B-dependent pathway in human chondrosarcoma cells Biochemical Pharmacology 2008 75 6 1292 1301
69. Hou C.-H., Chiang Y.-C., Fong Y.-C., Tang C.-H., WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells Biochemical Pharmacology 2011 81 11 1286 1295
70. Papachristou D. J., Papachristou G. J., Papaefthimiou O. A., Agnantis N. J., Basdra E. K., Papavassiliou A. G., The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF Histopathology 2005 47 6 565 574 (Pubitemid 41775178)